4 results match your criteria tgct foot

  • Page 1 of 1

Management of tenosynovial giant cell tumour of the foot and ankle.

Bone Joint J 2021 Apr;103-B(4):788-794

Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Aims: Tenosynovial giant cell tumour (TGCT) is one of the most common soft-tissue tumours of the foot and ankle and can behave in a locally aggressive manner. Tumour control can be difficult, despite the various methods of treatment available. Since treatment guidelines are lacking, the aim of this study was to review the multidisciplinary management by presenting the largest series of TGCT of the foot and ankle to date from two specialized sarcoma centres. Read More

View Article and Full-Text PDF

Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease.

J Am Acad Orthop Surg Glob Res Rev 2020 11;4(11):e20.00028

From the Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY (Healey); Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Santa Monica, CA (Bernthal); and Department of Orthopedics, Leiden University Medical Center, Leiden, Netherlands (van de Sande).

Background: Patients with diffuse tenosynovial giant cell tumor (TGCT) face a high risk of recurrence, progression, and disability. This systematic review assesses the recent evidence of surgical, adjuvant, and systemic treatments for TGCT.

Methods: We searched PubMed and Ovid with the terms "Giant cell tumor of tendon sheath" OR "pigmented villonodular synovitis" OR "tenosynovial giant cell" AND "treatment" OR "surgery. Read More

View Article and Full-Text PDF
November 2020

Incomplete resection increases the risk of local recurrence and negatively affects functional outcome in patients with tenosynovial giant cell tumor of the hindfoot.

Foot Ankle Surg 2020 Oct 5;26(7):822-827. Epub 2019 Dec 5.

Department of Orthopaedic Surgery, Nara Medical University, 840, Shijo-cho, Kashihara, Nara 634-8521, Japan.

Background: Diffuse tenosynovial giant cell tumors (TGCT) are more likely to occur in the hindfoot and tend to recur after surgical excision. We performed a pooled analysis of hindfoot TGCT cases to identify factors associated with local recurrence and functional outcomes.

Methods: We retrospectively reviewed medical records of 33 patients diagnosed with TGCT (15, localized cases; 18 diffused cases) of the hindfoot between 1998 and 2017. Read More

View Article and Full-Text PDF
October 2020

Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease.

Am J Surg Pathol 2000 Apr;24(4):479-92

Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

The clinical and pathologic features of 50 cases of diffuse-type tenosynovial giant cell tumor (D-TGCT), also known as extraarticular pigmented villonodular tenosynovitis (PVNTS), are presented. Patients' ages ranged from 4 to 76 years (median, 41 yrs), with a slight female predominance (28 women, 22 men). By definition, all lesions presented as predominant soft tissue masses, with or without an associated articular component. Read More

View Article and Full-Text PDF
  • Page 1 of 1